FDA Clearance Tracker · P160037-S021
Onclarity HPV Assay
Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Mar 12, 2025
Approved
Time to decision
29 days
Received Feb 11, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P160037-S021
- Device name
- Onclarity HPV Assay
- Applicant
- Becton, Dickinson and Company
- Applicant location
- Sparks, MD
- Received
- Feb 11, 2025
- Decided
- Mar 12, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P160037
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval of the SHIP-Sub-Protocol LMI-001-A-S01_Version 3.0 for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P160037-S017.
Source documents
Other decisions for Becton, Dickinson and Company
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K252344 · Decided Oct 16, 2026 · 445 days after receipt
Device type: Tubes, Vials, Systems, Serum Separators, Blood Collection (JKA) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.